Transition to newer clot-busting drug improves patient outcomes, lowers cost in treating ischemic stroke

A newer-generation clot-busting drug called tenecteplase outperforms the traditional treatment for ischemic strokes in several key areas, including better health outcomes and lower costs, according to a new study published today in the American Stroke Association's journal Stroke.

source https://medicalxpress.com/news/2022-09-transition-clot-busting-drug-patient-outcomes.html